nimodipine has been researched along with Central Nervous System Diseases in 6 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nimodipine has no consistent effect on brain oxygen consumption or cortical ATP or phosphocreatine levels, although the ischemia-induced fall of brain ATP levels in gerbils or the lowering of intracellular brain pH in rabbits with focal cerebral ischemia were antagonized by the drug." | 2.38 | Pharmacological basis for the use of nimodipine in central nervous system disorders. ( Schuurman, T; Scriabine, A; Traber, J, 1989) |
| "Nimodipine (Nimotop) was administered to spontaneously hypertensive rats (SHR) in order to investigate its ameliorative effect on central nervous disorders associated with hypertension." | 1.27 | Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats. ( Nomura, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tateishi, A | 2 |
| Scheller, MS | 2 |
| Drummond, JC | 2 |
| Zornow, MH | 2 |
| Grafe, MR | 2 |
| Fleischer, JE | 2 |
| Shapiro, HM | 2 |
| Calle, PA | 1 |
| Bogaert, MG | 1 |
| De Ridder, L | 1 |
| Buylaert, WA | 1 |
| Scriabine, A | 1 |
| Schuurman, T | 1 |
| Traber, J | 1 |
| Nomura, M | 1 |
1 review available for nimodipine and Central Nervous System Diseases
| Article | Year |
|---|---|
Pharmacological basis for the use of nimodipine in central nervous system disorders.
Topics: Aging; Animals; Anticonvulsants; Behavior, Animal; Brain; Brain Damage, Chronic; Brain Ischemia; Cen | 1989 |
5 other studies available for nimodipine and Central Nervous System Diseases
| Article | Year |
|---|---|
Failure of nimodipine to improve neurologic outcome after eighteen minutes of cardiac arrest in the cat.
Topics: Animals; Cats; Central Nervous System Diseases; Electroencephalography; Heart Arrest; Hemodynamics; | 1991 |
Nimodipine decreases resuscitability in a cardiopulmonary arrest model in the rat.
Topics: Animals; Central Nervous System Diseases; Heart Arrest; Nimodipine; Rats; Rats, Inbred Strains; Resu | 1991 |
[Drug for the control of stroke may help AIDS patients].
Topics: Acquired Immunodeficiency Syndrome; Central Nervous System Diseases; Humans; Nimodipine | 1990 |
Nimodipine does not improve neurologic outcome after 14 minutes of cardiac arrest in cats.
Topics: Animals; Brain; Cats; Central Nervous System Diseases; Electroencephalography; Heart Arrest; Nimodip | 1989 |
Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats.
Topics: Animals; Behavior, Animal; Blood Pressure; Central Nervous System Diseases; Discrimination Learning; | 1988 |